News

NEW YORK, NY and LEXINGTON, MA, April 8, 2021 – Royalty Pharma plc (Nasdaq: RPRX) (“Royalty Pharma”) and Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (“Dicerna”) today announced that Royalty Pharma has acquired Dicerna’s royalty interest in OXLUMO™ (lumasiran) for an upfront cash payment of

NEW YORK, NY, April 1, 2021 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a royalty interest in the cabozantinib products Cabometyx and Cometriq from GlaxoSmithKline (GSK) for an upfront payment of $342 million and up to $50 million in additional payments contingent on

NEW YORK, NY, March 30, 2021 – The Board of Directors of Royalty Pharma plc (Nasdaq: RPRX) today announced that the independent directors of the Board have unanimously appointed Henry A. Fernandez as Lead Independent Director. Mr. Fernandez is Chairman and Chief Executive Officer of MSCI Inc.

NEW YORK , Feb. 17, 2021 - Double-digit growth in Net cash provided by operating activities (GAAP) and Adjusted Cash Flow $2.4 billion of acquisitions announced in 2020; maintained leading share of biopharma royalty funding market Increasing outlook for 2020-2025 Adjusted Cash Receipts CAGR to 7%-10%

NEW YORK, NY, January 22, 2021 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter 2020 financial results on Wednesday, February 17, 2021 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m.

NEW YORK, NY and WALTHAM, MA, January 19, 2021 – Royalty Pharma plc (Nasdaq: RPRX) and Minerva Neurosciences, Inc. (Nasdaq: NERV) today announced that Royalty Pharma will acquire Minerva’s royalty interest in seltorexant for an upfront payment of $60 million and up to $95 million in additional

NEW YORK, NY, January 8, 2021 - Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2021 of $0.17 per class A share, reflecting a 13% increase in the company’s quarterly dividend over the previous quarter’s dividend.

NEW YORK, NY – JANUARY 7, 2021 - Royalty Pharma plc (Nasdaq: RPRX) today announced that management will present at the 39 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 10:50 a.m. EST. Investors, analysts, members of the media and the general public are invited to

NEW YORK, NY, December 22, 2020 – Royalty Pharma plc (Nasdaq: RPRX) today announced charitable contributions totaling $7,660,000 to support important COVID-19 research at The Rockefeller University, Mount Sinai Health System and Columbia University. This amount includes donations from Royalty

NEW YORK, NY, December 21, 2020 – Royalty Pharma (Nasdaq: RPRX) today announced a charitable contribution by Royalty Pharma in the amount of $1,000,000 to Mount Sinai Health System. The funds will be used to support: Mount Sinai’s Center for Post-COVID Care (CPCC) and Post-COVID Registry:   Royalty